ArticleScientific reports2026
Distinct genomic, microenvironmental, and nephron signatures in VHL kidney cysts and tumors.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dual loss of VHL and RASSF1A enhances tumorigenicity in clear cell renal cancer.Frontiers in oncology · 2026Article
- Integrative oxidative stress-disulfidptosis analysis identifiesFrontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with von Hippel-Lindau (VHL) disease develop multiple distinct kidney cysts and clear cell renal cell carcinomas (ccRCCs) throughout their lifetime. Although cysts are typically considered precursors of ccRCC, no molecular evidence of cysts to tumor progression was provided to date, due to the lack of an accurate molecular characterization of these lesions. We performed a comprehensive molecular characterization of four kidney cysts and six ccRCCs obtained from the same VHL-disease patient, thus all sharing the same genetic germline and host environment. We combined whole genome sequencing (WGS) and RNA sequencing (RNA-seq) profiling with pathological examinations. Cysts and tumors exhibited distinct transcriptomic profiles. Tumors showed increased glycolysis and response to hypoxia, while cysts were associated with enrichment in extracellular matrix organization and inflammation and displayed elevated expression of nephron distal portion markers. Deconvolution analysis further revealed different stromal and immune microenvironments with cysts enriched in myofibroblasts and plasma cells signatures whereas tumors were associated with tumor-associated macrophages (TAMs) and tumor vasculature signatures. Genomically, most cysts and tumors were clonally independent, harboring distinct somatic single-nucleotide variants. Despite sharing some somatic mutational signatures, tumors and cysts exhibited divergent somatic copy number alterations. Only tumors displayed chromosome 3p loss, resulting in VHL loss of heterozygosity, without other driver mutations. VHL patients develop multiple kidney cysts and solid tumors throughout their lifetime and their clinical management is challenging. This study presents the first in-depth molecular analysis of kidney cysts and ccRCC in a single VHL patient. We observed distinct molecular profiles between cysts and tumors, suggesting independent origins. While preliminary, these findings challenge the assumption that cysts always serve as precursors of ccRCC in VHL disease and underscore the need for larger studies to improve surveillance and management of renal lesions in patients with VHL disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.